Maximilian Reichert

13PUBLICATIONS
105CO-AUTHORS
Molecular targetsInnate immunityCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Aug 12, 2026
Targeting PRMT5 inhibitor-induced adaptation in pancreatic cancer with the RBM39 degrader indisulam.

|Jul 20, 2026
LSD1-GLS2 axis drives subtype-specific chemoresistance in pancreatic cancer through glutaminolysis reprogramming.

|Jul 20, 2026
Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond.

|Jun 15, 2026
Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis.

|Jun 01, 2026
Autophagy supports the storage of lytic granules in human NK cells.

|Jan 08, 2026
TIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength.

Martina Spiga, Alessia Potenza, Zulma Magnani

Pageof 3

Frequent Collaborators

5 joint publications

Dieter Saur

4 joint publications

Günter Schneider

3 joint publications

Aristeidis Papargyriou

2 joint publications

Katja Steiger